Kuala Lumpur, 19 February 2026 – Shares of Duopharma Biotech Bhd surged to a three-year high following the group’s recent contract wins with the Ministry of Health (MOH) for insulin products and injections, lifting the stock 3.38% to RM1.53 (approximately EUR 0.32) and valuing the company at RM1.47 billion (approximately EUR 308.7 million). One of the contracts, worth RM65.1 million (approximately EUR 13.68 million) for recombinant human insulin until May 2026 and another worth RM52.5 million (approximately EUR 11.03 million) for insulin injections until Feb 2028.Source - https://theedgemalaysia.com/node/793314 (ICE KUALA LUMPUR)

Fonte notizia: 19 febbraio 2026, Kuala Lumpur